Freedom of Information Request: 0823 2020/21
University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.
I have a Freedom of Information request. Could you please answer the questions below?
Queen Elizabeth Hospital Birmingham:
- In your Trust how many patients have been treated with the following Somatostatin Analogues in the latest 12-month period for which data are available?
- Octreotide – 236
- Lanreotide – 83
- Pasireotide – 0
- In the latest 12-month period how many Acromegaly patients have been treated with the following drugs?
- Sandostatin LAR – 0
- Octreotide Long-Acting (Generic) – 0
- Somatuline Autogel – 0
- Pasireotide – 0
- Pegvisomant – 0
- How many patients have received a somatropin treatment for growth hormone deficiency in the latest 12-month period?
- Genotropin – 1
- Humatrope – 0
- Norditropin – 0
- Nutropin – 1
- Omnitrope – 0
- Saizen – 0
- Zomacton – 0
- If it is possible, can you provide the number of patients under the age 16 that were treated with each of the following drugs in the latest 12-month period?
- Genotropin – 0
- Humatrope – 0
- Norditropin – 0
- Nutropin – 0
- Omnitrope – 0
- Saizen – 0
- Zomacton – 0
Heartlands, Good Hope and Solihull Hospitals:
- In your Trust how many patients have been treated with the following Somatostatin Analogues in the latest 12-month period for which data are available?
- Octreotide – 25
- Lanreotide – 2
- Pasireotide – 0
- In the latest 12-month period how many Acromegaly patients have been treated with the following drugs? We are unable to provide data by diagnosis.
- Sandostatin LAR
- Octreotide Long-Acting (Generic)
- Somatuline Autogel
- Pasireotide
- Pegvisomant
- How many patients have received a somatropin treatment for growth hormone deficiency in the latest 12-month period? We are unable to provide by diagnosis – the numbers below are for all issues
- Genotropin – 10
- Humatrope – 1
- Norditropin – 23
- Nutropin – 11
- Omnitrope – 0
- Saizen – 10
- Zomacton – 8
- If it is possible, can you provide the number of patients under the age 16 that were treated with each of the following drugs in the latest 12-month period?
- Genotropin – 6
- Humatrope – 1
- Norditropin – 9
- Nutropin – 11
- Omnitrope – 0
- Saizen – 9
- Zomacton – 8
